Treatment outcomes of sinonasal tumours with neuroendocrine features
DOI:
https://doi.org/10.18203/issn.2454-5929.ijohns20210151Keywords:
Olfactory neuroblastoma, Sinonasal cancer, Sinonasal neuroendocrine carcinoma, Sinonasal undifferentiated carcinomaAbstract
Background: Sinonasal tumours with neuroendocrine immunophenotype include olfactory neuroblastoma (ONB), sinonasal neuroendocrine carcinoma (SNEC) and sinonasal undifferentiated carcinoma (SNUC). These neoplasms usually present in advanced stages and are associated with poor outcome. This study describes the clinical features of these tumours and analyzes treatment outcomes of patients with these malignancies.
Methods: Retrospective chart review of all patients with sinonasal tumours diagnosed from 2009 to 2019, in a tertiary cancer centre. Clinical and histopathological prognostic factors were determined by univariate analysis. Overall survival was estimated using Kaplan-Meier method.
Results: A total of 27 patients (77.8% male) with a mean age of 52.0±16.8 years were included in the study. ONB was diagnosed in 9 patients, SNEC in 10 patients and SNUC in 8 patients. TNM stage IV disease was found in 20 patients (74.0%) at presentation. According to staging and treatment results, curative therapy was attempted in 21 patients (77.8%), of whom sixteen (76.2%) received multimodality treatment. Overall mean survival was 49 months and 1-year, 3-years and 5-years overall survival rates were 70.5%, 47.3% and 37.8%, respectively. Patients with SNEC had worse overall survival (p=0.044). Regarding treatment options, patients with SNUC treated with surgery and adjuvant radiation therapy had improved overall survival (p=0.027), as well as patients with SNEC selected for endoscopic resection surgery (p=0.049).
Conclusions: Accurate histologic diagnosis, grading, and clinical staging are essential for characterization and treatment selection in this heterogeneous group of sinonasal tumours. Consensus in the management of these tumours is lacking due to their rarity, difficulties in diagnosis and diverse current treatment approaches.
Metrics
References
Renner G. Small cell carcinoma of the head and neck: a review. Semin Oncol. 2007;34(1):3-14.
Bell D, Hanna EY, Weber RS, DeMonte F, Triantafyllou A, Lewis JS Jr, et al. Neuroendocrine neoplasms of the sinonasal region. Head Neck. 2016;38(1):E2259-66.
Uccella S, Ottini G, Facco C, Maragliano R, Asioli S, Sessa F, et al. Neuroendocrine neoplasms of the head and neck and olfactory neuroblastoma. Diagnosis and classification. Pathologica. 2017;109(1):14-30.
Su SY, Bell D, Hanna EY. Esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma: differentiation in diagnosis and treatment. Int Arch Otorhinolaryngol. 2014;18(2):S149-56.
Rosenthal DI, Barker JL Jr, El-Naggar AK, Glisson BS, Kies MS, Diaz EM Jr, et al. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer. 2004;101(11):2567-73.
Xu B, Chetty R, Perez-Ordoñez B. Neuroendocrine neoplasms of the head and neck: some suggestions for the new WHO classification of head and neck tumors. Head Neck Pathol. 2014;8(1):24-32.
van der Laan TP, Bij HP, van Hemel BM, Plaat BE, Wedman J, van der Laan BF, et al. The importance of multimodality therapy in the treatment of sinonasal neuroendocrine carcinoma. Eur Arch Otorhinolaryngol. 2013;270(9):2565-8.
AJCC. Cancer Staging Manual. 8th edn. Springer International Publishing: American Joint Commission on Cancer; 2017.
Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope. 1992;102(8):843-9.
Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery. 1993;32(5):706-14.
Hyams VJ. Tumors of the upper respiratory tract and ear. In: Hyams VJ, Betsakis JG, Michaels L, eds. Atlas of tumor pathology, 2nd series, fascicle 25. Washington: Armed Forces Institute of Pathology; 1988.
Dutta R, Dubal PM, Svider PF, Liu JK, Baredes S, Eloy JA. Sinonasal malignancies: a population-based analysis of site-specific incidence and survival. Laryngoscope. 2015;125(11):2491-7.
Mills SE. Neuroectodermal neoplasms of the head and neck with emphasis on neuroendocrine carcinomas. Mod Pathol. 2002;15(3):264-78.
van der Laan TP, Iepsma R, Witjes MJ, van der Laan BF, Plaat BE, Halmos GB. Meta-analysis of 701 published cases of sinonasal neuroendocrine carcinoma: The importance of differentiation grade in determining treatment strategy. Oral Oncol. 2016;63:1-9.
Bell D, Saade R, Roberts D, Ow TJ, Kupferman M, DeMonte F, et al. Prognostic utility of Hyams histological grading and Kadish-Morita staging systems for esthesioneuroblastoma outcomes. Head Neck Pathol. 2015;9(1):51-9.
Bell D. Sinonasal neuroendocrine neoplasms: current challenges and advances in diagnosis and treatment, with a focus on olfactory neuroblastoma. Head Neck Pathol. 2018;12(1):22-30.
Mitchell EH, Diaz A, Yilmaz T, Roberts D, Levine N, DeMonte F, et al. Multimodality treatment for sinonasal neuroendocrine carcinoma. Head Neck. 2012;34(10):1372-6.
Smith SR, Som P, Fahmy A, Lawson W, Sacks S, Brandwein M. A clinicopathological study of sinonasal neuroendocrine carcinoma and sinonasal undifferentiated carcinoma. Laryngoscope. 2000;110(10.1):1617-22.
Fiani B, Quadri SA, Cathel A, Farooqui M, Ramachandran A, Siddiqi I, et al. Esthesioneuroblastoma: a comprehensive review of diagnosis, management, and current treatment options. World Neurosurg. 2019;126:194-211.
Mendenhall WM, Mendenhall CM, Riggs CE Jr, Villaret DB, Mendenhall NP. Sinonasal undifferentiated carcinoma. Am J Clin Oncol. 2006;29(1):27-31.
Elkhatib AH, Soldatova L, Carrau RL, Hachem RA, Ditzel L, Campbell R, et al. Role of (18) F-FDG PET/CT differentiating olfactory neuroblastoma from sinonasal undifferentiated carcinoma. Laryngoscope. 2017;127(2):321-4.
Cohen ZR, Marmor E, Fuller GN, DeMonte F. Misdiagnosis of olfactory neuroblastoma. Neurosurg Focus. 2002;12(5):e3.
Shah K, Perez-Ordóñez B. Neuroendocrine Neoplasms of the Sinonasal Tract: Neuroendocrine Carcinomas and Olfactory Neuroblastoma. Head Neck Pathol. 2016;10(1):85-94.
Cordes B, Williams MD, Tirado Y, Bell D, Rosenthal DI, Al-Dhahri SF, et al. Molecular and phenotypic analysis of poorly differentiated sinonasal neoplasms: an integrated approach for early diagnosis and classification. Hum Pathol. 2009;40(3):283-92.
Iezzoni JC, Mills SE. “Undifferentiated” small round cell tumors of the sinonasal tract: differential diagnosis update. Am J Clin Pathol. 2005;124:S110-21.
Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer. 1976;37(3):1571-6.
Musy PY, Reibel JF, Levine PA. Sinonasal undifferentiated carcinoma: the search for a better outcome. Laryngoscope. 2002;112(8.1):1450-5.
Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, McIntyre J, Adams J, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer. 2002;94(10):2623-34.
Patel SG, Singh B, Stambuk HE, Carlson D, Bridger PG, Cantu G, et al. Craniofacial surgery for esthesioneuroblastoma: report of an international collaborative study. J Neurol Surg B Skull Base. 2012;73(3):208-20.
Tanzler ED, Morris CG, Orlando CA, Werning JW, Mendenhall WM. Management of sinonasal undifferentiated carcinoma. Head Neck. 2008;30(5):595-9.
Ow TJ, Bell D, Kupferman ME, Demonte F, Hanna EY. Esthesioneuroblastoma. Neurosurg Clin N Am. 2013;24(1):51-65.
Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001;2(11):683-90.
Ow TJ, Hanna EY, Roberts DB, Levine NB, El-Naggar AK, Rosenthal DI, et al. Optimization of long-term outcomes for patients with esthesioneuroblastoma. Head Neck. 2014;36(4):524-30.
Suriano M, De Vincentiis M, Colli A, Benfari G, Mascelli A, Gallo A. Endoscopic treatment of esthesioneuroblastoma: a minimally invasive approach combined with radiation therapy. Otolaryngol Head Neck Surg. 2007;136(1):104-7.
Castelnuovo PG, Delù G, Sberze F, Pistochini A, Cambria C, Battaglia P, et al. Esthesioneuroblastoma: endonasal endoscopic treatment. Skull Base. 2006;16(1):25-30.
Lund V, Howard DJ, Wei WI. Endoscopic resection of malignant tumors of the nose and sinuses. Am J Rhinol. 2007;21(1):89-94.
Polin RS, Sheehan JP, Chenelle AG, Munoz E, Larner J, Phillips CD, et al. The role of preoperative adjuvant treatment in the management of esthesioneuroblastoma: the University of Virginia experience. Neurosurgery. 1998;42(5):1029-37.
Mehta GU, Raza SM, Su SY, Hanna EY, DeMonte F. Management of olfactory neuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma involving the skullbase. J Neurooncol. 2020.
Frierson HF Jr, Mills SE, Fechner RE, Taxy JB, Levine PA. Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma. Am J Surg Pathol. 1986;10(11):771-9.
Amit M, Abdelmeguid AS, Watcherporn T, Takahashi H, Tam S, Bell D, et al. Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol. 2019;37(6):504-12.
Rischin D, Porceddu S, Peters L, Martin J, Corry J, Weih L. Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. Head Neck. 2004;26(5):435-41.
Lin EM, Sparano A, Spalding A, Eisbruch A, Worden FP, Heth J, et al. Sinonasal undifferentiated carcinoma: a 13-year experience at a single institution. Skull Base. 2010;20(2):61-7.
Fried D, Zanation AM, Huang B, Hayes N, Morris DE, Rosenman J, et al. Management of nonesthesioneuroblastoma sinonasal malignancies with neuroendocrine differentiation. Laryngoscope. 2012;122(10):2210-5.
de Bonnecaze G, Verillaud B, Chaltiel L, Fierens S, Chapelier M, Rumeau C, et al. Clinical characteristics and prognostic factors of sinonasal undifferentiated carcinoma: a multicenter study. Int Forum Allerg Rhinol. 2018;8(9):1065-72.
Bell D, Hanna EY. Sinonasal undifferentiated carcinoma: morphological heterogeneity, diagnosis, management and biological markers. Expert Rev Anticancer Ther. 2013;13(3):285-96.
Schmidt C, Potter N, Porceddu S, Panizza B. Olfactory neuroblastoma: 14-year experience at an Australian tertiary centre and the role for longer-term surveillance. J Laryngol Otol. 2017;131(S2):S29-s34.
Downloads
Published
How to Cite
Issue
Section
